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Lysosomal arylsulfatase A (ASA, EC 3.1.6.8) is a member of a large sulfatase family
– enzymes hydrolyzing sulfate ester bonds in numerous structurally very different sul-
fated compounds (1). Crystal structure of human arylsulfatase A was determined in
1998 and the catalytic mechanism of ASA was suggested and described in detail (2).
Physical and chemical properties of ASA have been extensively studied in biological
samples of different species (1–4). Also, the catalytic mechanism of ASA was confirmed
by kinetic studies of numerous active site mutants (5, 6). However, only a few reports
dealing with ASA kinetics in human disorders with decreased ASA activity have been
published (7–10).
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Activity and kinetics of arylsulfatase A (ASA, EC 3.1.6.8)
were analyzed in leukocyte homogenates derived from
patients suffering from cerebral palsy. Lower ASA activ-
ity was found in the patients’ leukocytes than in con-
trols, as determined by spectrophotometry using chro-
mogenic substrate p-nitrocatechol sulfate (p-NCS).
Kinetic parameters, Km and vmax, for leukocyte ASA we-
re determined from the dependence of initial reaction
velocities on the p-NCS concentrations. A slight differen-
ce in Km values was found for leukocyte enzyme in cere-
bral palsy (0.26 mmol L–1) compared to the control (0.21
mmol L–1), whereas vmax value for leukocyte ASA in dis-
ease reached only 58% of the control value. In addition,
the presence of the most common mutations associated
with ASA pseudodeficiency (N350S, 1524+95 A>G) and
metachromatic leukodystrophy (P426L) was detected in
all investigated patients. Changes in activity and kinetic
parameters of leukocyte ASA in cerebral palsy are most
probably related to the decrease of enzyme concentra-
tion; the detected mutations might at least partially con-
tribute to the observed changes.
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Activity and kinetics of ASA are studied using synthetic substrates: chromogenic
p-nitrocatechol sulfate or fluorigenic 4-methylumbelliferyl sulfate. The major physiolo-
gical substrate of lysosomal ASA is cerebroside-3-sulfate, an important lipid constituent
of oligodendrocyte membranes contributing to the maintenance of myelin sheath integ-
rity. ASA deficiency causes metachromatic leukodystrophy (MLD), a rare autosomal re-
cessive disorder characterized by the storage of cerebroside sulfate mainly in the ner-
vous tissue. Pathologically, a progressive demyelination occurs, causing various neurolog-
ical symptoms such as pyramidal and extrapyramidal signs, progressive spastic quadri-
paresis, etc. (1).
In addition to mutations found to be the most frequent ones in European MLD pa-
tients (P426L and 459+1G>A) and mutations responsible for the majority of arylsulfatase
A pseudodeficiency (ASA-PD) alleles (N350S and 1524+95 A>G), a large number of
other mutations and polymorphisms in the ASA gene, resulting in different levels of de-
creased enzyme activity, have been reported so far (11–13). However, only several muta-
tions have been characterized with regard to catalytic properties of the enzyme due to
changes in either conformation or concentration of the enzyme (14).
Cerebral palsy is a neurodevelopmental disorder with complex ethiopathogenesis.
It affects body movement and muscle coordination and is caused by the damage and/or
faulty development of motor areas in the brain. Previous clinical observations have sho-
wed that arylsulfatase A activity is decreased in leukocytes derived from patients suffer-
ing from cerebral palsy (15). According to available data, arylsulfatase A kinetics has not
yet been studied in human leukocytes derived either from patients with cerebral palsy
or other disorders accompanied by decreased ASA activity. The aim of this preliminary
study was to determine the kinetic parameters of leukocyte ASA and to elucidate whe-
ther possible changes of ASA kinetic properties may explain the decreased leukocyte
ASA activity in patients with cerebral palsy.
EXPERIMENTAL
Materials
Substrate for determination of the enzyme activity and the kinetic assay, p-nitroca-
techol sulfate (p-NCS), was purchased from Sigma-Aldrich (USA). Bovine serum albu-
min (BSA) of 98% purity was also obtained from Sigma-Aldrich. Specific primers, DNA
standards and restriction enzymes were purchased from Invitrogen and Promega (USA).
The PCR amplification mixture was purchased from Takara Bio. Inc. (Japan). All other
chemicals were of analytical grade.
Subjects
Blood samples were obtained by venipuncture from individuals with cerebral palsy
(N = 4; age range: 3–10 years; 2 females, 2 males) and healthy individuals (N = 3; age
range: 10–26 years; 2 females, 1 male). Blood was collected in duplicate during morning
hours and before giving any medications. The local ethical committee approved the stu-
dy.
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Isolation of leukocytes
A slightly modified method of Haltia et al. and Bass et al. was used for isolation and
homogenization of leukocytes (16, 17). Briefly, 5–7 mL of venous blood was drawn to a
test tube containing 1 mL of dextran. The samples were allowed to stand at room tem-
perature for 45 minutes for sedimentation of erythrocytes and the suspension of leuko-
cytes. Pure leukocyte pellets were obtained after centrifugation of the upper plasma
layer, separation of leukocyte pellets from the serum, and additional washing with
haemolytic buffer. Leukocyte pellets were dispersed in 0.25% Triton X-100 and homoge-
nized. Determination of the protein content in leukocyte homogenates was performed
according to Lowry’s method using bovine serum albumin (BSA, 1 mg mL–1) as a stan-
dard (18).
Determination of ASA activity
The activity of arylsulfatase A was determined in leukocyte homogenates by
spectrophotometry (l = 515 nm) using 10 mmol L–1 p-nitrocatechol sulfate (p-NCS) as a
chromogenic substrate, as described by Jordan et al. (19). The ASA activities were ex-
pressed as nanomoles of the formed p-nitrocatechol (p-NC) per mg protein per hour.
ASA kinetic analysis
Assays were conducted at 36.5 °C in a final volume of 700 µL, containing aliquots of
leukocyte homogenate (75 µg of protein) and substrate (p-NCS) solution. The substrate
was dissolved in 0.5 mol L–1 acetate buffer (pH 5.0) containing 0.5 mmol L–1 sodium
pyrophosphate (Na4P2O7) and 10% sodium chloride. The substrate concentration ranged
from 0.2 to 9.0 mmol L–1. Absorbance of the released p-NC was continuously monitored
for 5 min at 515 nm and the reaction rate was determined from the initial slope. Absorp-
tion measurements were performed against appropriate substrate blanks on a Unicam
UV/Vis spectrophotometer UV4-100 (UK) with thermostated cell holders in 1 cm silica-
-glass cells. Measurements were performed in duplicate for each substrate concentration.
Kinetic parameters, Km and vmax, were calculated by the non-linear regression analysis
from the dependence of the initial reaction rate on the substrate concentration. This cal-
culation was performed using the PeakFit software, which – by the iteration procedure –
calculates the most correct vmax and Km values based on experimental points and the
Michaelis-Menten equation. Calculated vmax values were expressed in mmol L–1 of p-NC
liberated per minute at 36.5 °C per mg of total leukocyte proteins.
DNA isolation and PCR amplification
Genomic DNA was extracted from leukocytes and fragments of the ASA gene were
amplified using specific primers (11, 12).
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Determination of the N350S and 1524+95 A>G mutations associated with
arylsulfatase A pseudodeficiency
The N350S and 1524+95 A>G mutations were determined according to the previously
described procedure (12). Briefly, PCR products were digested with BsrSI and DdeI, respec-
tively. In the presence of the N350S mutation, the 275 bp fragment A (allele 2) is cleaved to
two smaller fragments of 161 bp and 114 bp (allele 1). Fragment B of 114 bp (allele 2) gene-
rates the 97 bp fragment (allele 1) in the presence of the 1524+95 A>G mutation.
Determination of the P426L mutation associated with metachromatic leukodystrophy
The P426L mutation was analyzed using the restriction enzyme PstI, as previously
described (11). In the presence of the mutation, the 100 bp fragment (allele 2) is cleaved
to 70 bp and 26 bp (allele 1).
Statistics
Student’s t-test (Cochran and Cox modification) was used.
RESULTS AND DISCUSSION
Kinetic parameters of arylsulfatase A in leukocytes
In our study of leukocyte ASA kinetics, the initial reaction rate was found to be
lower in leukocytes of the patients with cerebral palsy than in the controls, as shown by
the progress curves of the ASA catalyzed reactions (Fig. 1). Results of the performed
ASA kinetic study showed that, in case of leukocytes of both healthy individuals and pa-
tients, Km values of the enzyme toward p-NCS are in the range previously reported for
ASA in human tissues (0.20–0.60 mmol L–1) (Table I) (20). Also, comparable values for
the Km of ASA from patients’ leukocytes (Km = 0.26 mmol L–1) and control leukocytes
(Km = 0.21 mmol L–1) might indicate that no change in enzyme affinity of ASA occurred
in spastic cerebral palsy (Table I). On the other hand, a significant decrease of the vmax
value was found in cerebral palsy (8.44 mmol L–1 min–1 mg–1) compared to the control
value (14.53 mmol L–1 min–1 mg–1) (Fig. 2 and Table I).
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Table I. Kinetic parameters of arylsulfatase A in leukocytes derived from healthy individuals and patients
with the diagnosis of cerebral palsy
Km (mmol L–1)a vmax (mmol L–1 min–1 per mg protein)a
Control (N = 3) 0.21 ± 0.02 14.53 ± 2.02
Cerebral palsy (N = 4) 0.26 ± 0.03 8.44 ± 0.76b
N – number of individuals.
a Mean ± SD.
b Statistically significant difference in comparison with the control (p < 0.01).
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Fig. 1. Progress curves of the ASA
catalyzed reactions showing in-
dividual differences between
samples derived from the con-
trols and patients with cerebral
palsy (c(p-NCS) = 7.01 mmol L–1,





































Fig. 2. Dependence of the initial reaction rate on the substrate concentration (36.5 °C, pH 5.0, dupli-
cate measurements). vmax values are expressed as mmol L–1 of p-NC liberated per minute per mg of
total leukocyte proteins.
Only a few studies have dealt with the kinetics of arylsulfatase A in human disor-
ders characterized by low ASA activity and caused by mutations in the ASA gene (7–9).
In those studies no substantial changes in Km, pH optima or heat stability of the enzyme
analyzed from skin fibroblasts were found between the controls and patients with ASA
pseudodeficiency or metachromatic leukodystrophy. However, a more recent study, also
performed in skin fibroblasts derived from individuals with ASA pseudodeficiency and
controls, showed significant kinetic differences in both Km and heat inactivation proper-
ties of the enzyme in ASA pseudodeficiency (10). In our preliminary study of ASA kinet-
ics in leukocytes, the reaction of ASA with p-nitrocatechol sulfate was followed directly
from leukocyte homogenates derived from patients with cerebral palsy and from
healthy individuals. Experimental conditions were similar to those routinely used for
determination of leukocyte ASA activity for diagnostic purposes. In such conditions, op-
timal for the ASA activity, the activity of another lysosomal hydrolase, arylsulfatase B
(ASB), is minimized due to lower substrate concentration, lower pH and the presence of
sodium pyrophosphate and sodium chloride in the reaction mixture (20–22).
The presence of the N350S, 1524+95 A>G, P426L mutations and
arylsulfatase A activity
The observed decrease of the leukocyte ASA vmax in spastic cerebral palsy may be
related to the confirmed presence of three different mutations in the ASA gene. Namely,
additional genotyping was performed for the most common mutations associated with
arylsulfatase A pseudodeficiency (N350S and 1524+95 A>G mutations), and metachro-
matic leukodystrophy (P426L mutation). The results showed that each patient with the
diagnosis of spastic cerebral palsy was a heterozygous carrier of all three analyzed mu-
tations, while healthy individuals were found to be homozygous for normal alleles (Fig.
3 and Table II). Heterozygosity for a single analyzed mutation does not necessarily re-
sult in decreased enzyme activity. However, there is high probability that heterozigosity
for three different mutations in the arylsulfatase A gene would have an impact on the
ASA activity. This was indeed confirmed by a spectrophotometric determination of ASA
activity in leukocytes, showing that in samples derived from patients with cerebral pal-
sy arylsulfatase A decreased significantly and reached only 31% of the activity measured
in control samples (Table III).
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Table II. Arylsulfatase A pseudodeficiency and metachromatic leukodystrophy genotypes in patients with
the diagnosis of cerebral palsy and in healthy individuals
Genotypea
N350S 1524+95 A ® G P426L
1,1 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2
Cerebral palsy (N = 4) 0 4 0 0 4 0 0 4 0
Control (N = 3) 0 0 3 0 0 3 0 0 3
N – number of individuals.
a 1,1 – homozygous for mutant sequence; 1,2 – heterozygous; 2,2 – homozygous for normal sequence.
The decrease in ASA activity, as well as the decrease in the vmax value for leukocyte
ASA in cerebral palsy, most probably reflect a decrease of the total enzyme concentra-
tion. However, a change in the enzyme conformation as a consequence of the present
mutations could not be completely excluded. Namely, changes of the enzyme biochemi-
cal function resulting from the here analyzed mutations have been well described, caus-
ing either decreased stability of the enzyme within lysosomes (P426L mutation), or loss
of the polyadenylation site leading to reduction of ASAmRNA (1524+95 A>G mutation)
and loss of the N-glycosylation site (N350S mutation), with consequent probable distur-
bed targeting of the protein at lysosomes (23–25).
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Fig. 3. Specific restriction products shown in several analyzed samples derived from the controls
and subjects with the diagnosis of cerebral palsy: a) detection of the N350S mutation; b) detection of
the 1524+95 mutation A>G; c) detection of the P426L mutation. St 1 – DNA standard (100 bp); St 2 –
DNA standard (25 bp); 1,2 – heterozygous; 2,2 – homozygous for normal sequence.
Table III. Arylsulfatase A activity in leukocytes derived from healthy individuals and patients with the
diagnosis of cerebral palsy
ASA activity (nmol h–1 mg–1)a,b
Control (N = 3) 125 ± 27
Cerebral palsy (N = 4) 39 ± 5c
N – number of individuals.
a The ASA activity is expressed as nanomoles of the formed p-nitrocatechol (p-NC) per mg protein per hour.
b Mean ± SD.
c Statistically significant difference in comparison with the control (p < 0.05).
CONCLUSIONS
Decreased activity and vmax of leukocyte ASA in cerebral palsy are most probably
related to the decrease of enzyme concentration in disease, while the detected mutations
may contribute to the observed changes. Future research is directed to optimization of
the method used for the analysis of arylsulfatase A kinetic parameters directly from hu-
man leukocytes, which are easily and less aggressively obtained for diagnostic proce-
dures compared to bioptic material (skin fibroblasts). Such an optimized method for the
analysis of leukocyte ASA kinetics may provide additional information and a better in-
sight into the mechanism of the altered activity of this enzyme occurring in cerebral palsy.
Acknowledgements. – We thank Ms Ana ^a~i} for her skillful technical assistance. The work was
done within the 0108120 and 0108051 projects financed by the Croatian Ministry of Science, Educa-
tion and Sports.
REFERENCES
1. K. von Figura, V. Gieselmann and J. Jaeken, Metachromatic Leukodystrophy, in The Metabolic &
Molecular Bases of Inherited Diseases (Eds. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle),
McGraw-Hill, New York 2001, pp. 3695–3724.
2. G. Lukatela, N. Krauss, K. Theis, T. Selmer, V. Gieselmann, K. von Figura and W. Saenger, Crys-
tal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site
suggest a novel mechanism for sulfate ester hydrolysis, Biochemistry 37 (1998) 3654–3664.
3. A. B. Roy and T. J. Mantle, The anomalous kinetics of sulphatase A, Biochem. J. 261 (1989) 689–
697.
4. C. O’Fagain, B. M. Butler and T. J. Mantle, The effect of pH on the kinetics of arylsulphatases A
and B, Biochem. J. 213 (1983) 603–607.
5. M. Recksiek, T. Selmer, T. Dierks, B. Schmidt and K. von Figura, Sulfatases, trapping of the sul-
fated enzyme intermediate by substituting the active site formylglycine, J. Biol. Chem. 273 (1998)
6096–6103.
6. A. Waldow, B. Schmidt, T. Dierks, R. von Bülow and K. von Figura, Amino acid residues form-
ing the active site of arylsulfatase A. Role in catalytic activity and substrate binding, J. Biol.
Chem. 274 (1999) 12284–12288.
7. P. L. Chang and R. G. Davidson, Complementation of arylsulfatase A in somatic hybrids of me-
tachromatic leukodystrophy and multiple sulfatase deficiency disorder fibroblasts, Proc. Natl.
Acad. Sci. USA 77 (1980) 6166–6170.
8. P. L. Chang and R. G. Davidson, Pseudo arylsulfatase-A deficiency in healthy individuals: ge-
netic and biochemical relationship to metachromatic leukodystrophy, Proc. Natl. Acad. Sci. USA
80 (1983) 7323–7327.
9. B. Herz and G. Bach, Arylsulfatase A in pseudodeficiency, Hum. Genet. 66 (1984) 147–150.
10. Y. Qu, J. B. Miller, R. J. Desnick and E. Shapira, Arylsulfatase A pseudodeficiency: altered ki-
netic and heat-inactivation properties, Genet. Test. 4 (1997/98) 283–287.
11. J. Berger, B. Löschl, H. Bernheimer, A. Lugowska, A. Tylki-Szymanska, V. Gieselmann and B.
Molzer, Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with
metachromatic leukodystrophy, Am. J. Med. Genet. 69 (1997) 335–340.
12. M. L. Barth, C. Ward, A. Harris, A. Saad and A. Fensom, Frequency of arylsulphatase A pseu-
dodeficiency associated mutations in a healthy population, J. Med. Genet. 31 (1994) 667–671.
102
S. K. Bognar et al.: Kinetics and activity of arylsulfatase A in leukocytes derived from patients with a cerebral palsy, Acta Pharm. 56
(2006) 95–104.
13. B. Eng, T. Heshka, M. A. Tarnopolsky, L. M. Nakamura, M. J. Nowaczyk and J. S. Waye, Infan-
tile metachromatic leukodystrophy (MLD) in a compound heterozygote for the c.459 + 1G > A
mutation and a complete deletion of the ARSA gene, Am. J. Med. Genet. A 128 (2004) 95–97.
14. F. Schestag, A. Yaghootfam, M. Habetha, P. Poeppel, F. Dietz, R. A. Klein, J. Zlotogora and V.
Gieselmann, The functional consequences of mis-sense mutations affecting an intra-molecular
salt bridge in arylsulphatase A, Biochem. J. 367 (2002) 499–504.
15. Z. Grube{i}, Activity of Arylsulfatase A in Patients with Diagnosis of Cerebral Palsy, PhD Thesis,
University of Zagreb, Zagreb 2001.
16. T. Haltia, J. Palo, M. Haltia and A. Icen, Juvenile metachromatic leukodystrophy. Clinical, bio-
chemical and neuropathologic studies in nine new cases, Arch. Neurol. 37 (1980) 42–46.
17. N. H. Bass, E, J. Witmer and F. E. Dreifuss, A pedigree study of metachromatic leukodystrophy,
Neurology 20 (1970) 52–62.
18. O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, Protein measurement with the Folin
phenol reagent, J. Biol. Chem. 193 (1951) 265–275.
19. T. W. Jordan, B. Casey and H. J. Weston, Enzymic detection of metachromatic leukodystrophy
patients and heterozygotes, New Zeal. Med. J. 85 (1977) 369–372.
20. M. Balbaa, M. El-Kersh, H. Mansour, G. Yacout, M. Ismail, A. Malky, K. Bassiouny, N.
Abdel-Monem and K. Kandeel, Activity of some hepatic enzymes in schistosomiasis and con-
comitant alteration of arylsulfatase B, J. Biochem. Mol. Biol. 37 (2004) 223–228.
21. H. Baum, K. S. Dodgson and B. Spencer, The assay of arylsulphatases A and B in human urine,
Clin. Chim. Acta 4 (1959) 453–455.
22. E. Shapira and H. L. Nadler, Problems associated with the determination of arylsulfatase A and
B using nitrocatechol sulfate substrate, Clin. Chim. Acta 65 (1975) 1–4.
23. R. von Bülow, B. Schmidt, T. Dierke, N. Schwabauer, K. Schilling, E. Weber, I. Usón and K. von
Figura, Defective oligomerization of arylsulfatase A as a cause of its instability in lysosomes
and metachromatic leukodystrophy, J. Biol. Chem. 277 (2002) 9455–9461.
24. V. Gieselmann, A. Polten, J. Kreysing and K. von Figura, Arylsulfatase A pseudodeficiency:
Loss of a polyadenylylation signal and N-glycosylation site, Proc. Natl. Acad. Sci. USA 23 (1989)
9436–9440.
25. J. S. Harvey, W. F. Carey and P. Morris, Importance of the glycosylation and polyadenylation
variants in metachromatic leukodystrophy pseudodeficiency phenotype, Hum. Mol. Genet. 7
(1998) 1215–1219.
S A @ E T A K
Kinetika i aktivnost leukocitne arilsulfataze A u osoba s dijagnozom
cerebralne paralize
SVJETLANA KALANJ BOGNAR, BLA@ENKA FORETI], IVANA FURA^, @ELJKA VUKELI] i ZDRAVKO GRUBE[I]
Analizirane su aktivnost i kinetika arilsulfataze A (ASA, EC 3.1.6.8) u leukocitnim
homogenatima osoba oboljelih od cerebralne paralize. Spektrofotometrijskim odre|iva-
njem aktivnosti ASA prema kromogenom supstratu p-nitrokatehol sulfatu (p-NCS) utvr-
|ene su smanjene aktivnosti enzima u leukocitima oboljelih osoba. Kineti~ki parametri,
Km i vmax, leukocitne ASA odre|eni su iz ovisnosti po~etne brzine reakcije o koncentra-
ciji p-NCS. Utvr|ena je manja razlika izme|u Km vrijednosti enzima zdravih (0.21 mmol
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L–1) i oboljelih osoba (0.26 mmol L–1), dok je vrijednost vmax enzima u oboljelih iznosila
58% vrijednosti vmax enzima zdravih osoba. Tako|er je u svih ispitanika s dijagnozom
cerebralne paralize utvr|eno prisustvo naj~e{}ih mutacija povezanih s ASA pseudode-
ficijencijom (N350S, 1524+95 A>G) i metakromatskom leukodistrofijom (P426L). Promje-
ne aktivnosti i kineti~kih parametara leukocitne ASA u cerebralnoj paralizi najvjerojat-
nije su posljedica sni`ene koncentracije enzima; mogu}e je da na|ene mutacije barem
djelomi~no doprinose zapa`enim promjenama.
Klju~ne rije~i: arilsulfataza A, kineti~ki parametri, aktivnost enzima, mutacije u genu za arilsulfa-
tazu A, cerebralna paraliza
Medicinski fakultet Sveu~ili{ta u Zagrebu, Zagreb
Dje~ja bolnica za neurorazvojne poreme}aje »Goljak«, Zagreb
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